Preclinical Hematology R&D Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Coagulation and Bleeding Disorder Models for Preclinical Research

Inquiry

Ace Therapeutics specializes in preclinical contract research services for hematological diseases. Our in vivo coagulation and bleeding disorder models support pharmaceutical and biotechnology companies in evaluating the safety, efficacy, and mechanism of action of investigational drugs targeting hemostatic and thrombotic pathways.

Overview of In Vivo Coagulation and Bleeding Disorder Models

Blood coagulation is a tightly regulated physiological process involving platelets, coagulation factors, and the endothelium. Disruption of this system can result in various disorders, such as:

Hemophilia A and B
Von Willebrand Disease (vWD)
Thrombocytopenia
Anticoagulant-induced bleeding
Thrombotic disorders (e.g., DVT, PE)

Ace Therapeutics provides comprehensive in vivo services using validated animal models to assess procoagulant, anticoagulant, fibrinolytic, and hemostatic agents.

Available Animal Models and Applications

We offer a wide portfolio of animal models tailored to specific coagulation and bleeding disorders. Each model has been validated for key pharmacological endpoints, offering reliable platforms for mechanistic studies, dose-response assessments, and proof-of-concept evaluation.

Model	Animal Strain	Disease Simulated	Applications
Hemophilia A Model	FVIII knockout (C57BL/6)	Factor VIII deficiency	Recombinant FVIII testing, gene therapy validation
Hemophilia B Model	FIX knockout (C57BL/6 or BALB/c)	Factor IX deficiency	FIX replacement therapy evaluation
Von Willebrand Disease Model	VWF-deficient mice	Von Willebrand Disease	vWF replacement, desmopressin mimetics
Thrombocytopenia Model	Chemically induced	Platelet depletion	Platelet transfusion, thrombopoietin receptor agonists
FeCl₃-induced Arterial Injury	C57BL/6	Thrombosis	Antiplatelet, anticoagulant agents
Tail Bleeding Time Model	Various	Hemostatic capacity	General hemostatic assessment, dose-response studies

Integrated Workflow for Coagulation Studies

Study Design Consultation

We collaborate with clients to select optimal models based on mechanism of action (MoA), including species suitability, dosing regimen, and clinically translatable endpoints.

Model Implementation & Dosing

Disease induction with quality-controlled agents (e.g., warfarin, LPS)
Test article administration (IV/PO/SC routes supported)
Positive controls included (e.g., heparin in DVT models)

Multi-Parameter Endpoint Analysis

Coagulation Parameters: PT, APTT, thrombin time, specific factor assays
Fibrinolysis Markers: D-dimer, PAI-1, t-PA, plasmin-antiplasmin complexes
Bleeding Assessment: Template bleeding time, blood loss volume, hemoglobin dynamics
Thrombus Quantification: Weight, μCT imaging, histomorphometry (fibrin/RBC/platelet composition)
Tissue Analysis: IHC for fibrin deposition, TUNEL for endothelial apoptosis, organ function markers

Comprehensive Reporting

Data integration with statistical analysis (e.g., ANOVA for group comparisons), including PK/PD correlations when applicable.

Model Validation and Characterization

Each model is characterized using a combination of hematological, histopathological, and functional endpoints. Examples include:

Tail Bleeding Time Assay: Sensitive to changes in platelet function and coagulation factor levels.
Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM): Evaluate the viscoelastic properties of whole blood clotting.
Platelet Aggregation Assays: Used to assess platelet reactivity in thrombocytopenic or antiplatelet-treated animals.
Biomarker Profiling: Includes fibrinogen, D-dimer, thrombin-antithrombin complexes, and activated partial thromboplastin time (aPTT).

We routinely confirm gene knockouts via PCR and western blot, and we use imaging modalities such as intravital microscopy and Doppler ultrasound to assess vascular injury models.

Suitable Drug Categories for Evaluation

Our in vivo models are ideal for the preclinical assessment of:

Recombinant coagulation factors (e.g., FVIII, FIX)
Hemostatic agents (e.g., antifibrinolytics)
Anticoagulants (e.g., direct Xa and IIa inhibitors)
Gene therapies for inherited bleeding disorders
Platelet stimulants or inhibitors
Small molecule or biologic modulators of coagulation pathways

Ace Therapeutics combines deep expertise in hematology pathophysiology with robust preclinical models to advance your coagulation and bleeding disorder programs. Contact our scientific team today to discuss how we can support your next development challenge.

Frequently Asked Questions (FAQs)

How do I choose the right bleeding disorder model for my compound?

We offer expert consultation to align your drug's mechanism of action with the most relevant disease model. Selection depends on your therapeutic target, expected pharmacodynamics, and regulatory goals.

Are your models suitable for evaluating gene therapies?

Yes. Our hemophilia A and B knockout models are frequently used for testing gene therapy vectors, especially for long-term expression and functional correction studies.

Can you conduct comparative studies between multiple agents?

Absolutely. We design studies that include multiple treatment arms to benchmark your compound against standards or competitors.

Do you provide histopathology as part of the model evaluation?

Yes, histological assessment of clot formation, vessel integrity, or hemorrhage is included upon request.

What endpoints are typically used in thrombotic models?

Common endpoints include time to occlusion, thrombus weight, blood flow measurements, and platelet activation markers.